journal
MENU ▼
Read by QxMD icon Read
search

Pharmaceutical Patent Analyst

journal
https://www.readbyqxmd.com/read/28825514/patent-highlights-april-may-2017
#1
Hermann Am Mucke
A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.
August 21, 2017: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/28825509/pretargeting-immunotherapy-a-novel-treatment-approach-for-systemic-amyloidosis
#2
Jonathan S Wall, James S Foster, Emily B Martin, Stephen J Kennel
The amyloidoses are a complex group of disorders characterized by the deposition of proteinaceous amyloid fibrils in vital organs. The deposits are nonimmunogenic and may be composed of one of more than 35 proteins. We have developed a two-stage immunotherapeutic approach using peptides that recognize most, if not all, amyloid deposits to facilitate amyloid clearance. In the first embodiment, we have developed a bifunctional peptope to enhance and expand the utility of currently available antibodies. In the second, we have generated peptide-reactive antibodies that can be targeted to the amyloid deposits by peptides thereby providing alternative reagents for immunotherapy of amyloidosis...
August 21, 2017: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/28818024/enforceability-of-second-medical-use-claims-in-the-uk
#3
Tom Carver
No abstract text is available yet for this article.
August 18, 2017: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/28818023/pre-emptive-product-patentability-declarations
#4
Lorna Brazell
No abstract text is available yet for this article.
August 18, 2017: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/28818005/computational-biology-future-challenges-for-the-patenting-of-repurposed-drugs
#5
Bruce Bloom
No abstract text is available yet for this article.
August 18, 2017: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/28818001/pulmonary-drug-delivery-system-newer-patents
#6
Shahid Sukhbir Kaur
Inhalational route for drug delivery and desired effects has been known since centuries. This lung-targeted therapy has benefited asthmatics and those with chronic respiratory problems. The technique has evolved greatly from crude pots and pipes to modern sophisticated drug-dispensing devices. This mode is effective, rapid and safe. Its outcome, however, is majorly determined by drug formulation, device structure and patient's coordinating skill. In spite of great advances in this field, more efforts are required to meet the unmet needs...
August 18, 2017: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/28696180/epithelial-na-channel-inhibitors-for-the-treatment-of-cystic-fibrosis
#7
Nichola J Smith, Catherine F Solovay
The epithelial Na(+) channel (ENaC) is a key regulator of the volume of airway surface liquid (ASL) and is found in the human airway epithelium. In cystic fibrosis (CF), Na(+) hyperabsorption through ENaC, in the absence of cystic fibrosis transmembrane conductance regulator mediated anion secretion, results in the dehydration of respiratory secretions and the impairment of mucociliary clearance. The hypothesis of utilizing an ENaC blocking molecule to facilitate restoration of the airway surface liquid volume sufficiently to allow normal mucociliary clearance is of interest in the management of lung disease in CF patients...
July 11, 2017: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/28696178/a-cheat-sheet-to-navigate-the-complex-maze-of-pharmaceutical-exclusivities-in-europe
#8
Marta Cavero Tomas, Bo Peng
As the two leading markets for pharmaceutical and biotech companies, the USA and Europe offer incentives to stimulate drug innovation, including patent and regulatory exclusivities. These exclusivities extend periods during which companies can market their products free of generic or other competition and recoup their investment. Pharmaceutical and biotech companies should carefully assess the different types of exclusivities available when developing regulatory submissions, patent filing strategies. The authors have previously summarized the USA exclusivities in an earlier publication...
July 11, 2017: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/28696166/cellzdirect-gives-new-hope-for-patent-protection-for-personalized-medicine-in-the-usa
#9
Joan Ellis
No abstract text is available yet for this article.
July 11, 2017: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/28696157/toward-carbon-monoxide-based-therapeutics-carbon-monoxide-in-a-pill
#10
Xingyue Ji, Binghe Wang
As one of the three known gasotransmitters, carbon monoxide (CO) has demonstrated therapeutic potential against a wide range of human diseases. However, development of CO as a therapeutic agent is severely impeded, primarily due to the lack of pharmaceutically acceptable delivery forms of CO. Gaseous CO may only have limited utility under carefully controlled clinical environment. As a result, there have been efforts in developing metal-based CO-releasing molecules and organic CO-releasing molecules that require light activation...
July 11, 2017: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/28696148/3d-printing-of-pharmaceuticals-patent-and-regulatory-challenges
#11
James A Stones, Catherine M Jewell
No abstract text is available yet for this article.
July 11, 2017: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/28696142/patent-highlights-february-march-2017
#12
Hermann Am Mucke
No abstract text is available yet for this article.
July 11, 2017: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/28696149/immune-checkpoint-inhibitors-the-battle-of-giants
#13
Matthieu Collin
No abstract text is available yet for this article.
July 2017: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/28485681/humira-recent-developments
#14
Peter Norman
No abstract text is available yet for this article.
May 9, 2017: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/28485677/january-2017-extended-scope-of-patent-term-extension-japan-is-progenerics-debiopharm-international-sa-vs-towa-pharmaceutical-co-ltd
#15
Takeshi S Komatani
No abstract text is available yet for this article.
May 9, 2017: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/28485666/are-therapeutic-antibodies-still-patentable-at-the-european-patent-office
#16
Vicki Allen, Graham Matthew Lewis
No abstract text is available yet for this article.
May 9, 2017: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/28485665/patent-highlights-december-2016-january-2017
#17
Hermann Am Mucke
No abstract text is available yet for this article.
May 9, 2017: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/28485650/intellectual-property-and-biodiversity-interplay
#18
Ravi Bhola, Shreya Dave
Potentially divergent objectives and thereby obligations under the Convention on Biodiversity and Trade-Related Aspects of Intellectual Property Rights Agreement are also reflected in respective domestic legislations in India. The review article focuses on Biological Diversity Act, 2002 vis-à-vis Patents Act, 1970 of India with intricacies involved thereunder. Authors have analyzed the obligations under these domestic legislations. The article goes on to make a few suggestions to aid effective implementation of both the statutes...
May 9, 2017: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/28534435/genome-editing-technologies-and-patent-landscape-overview
#19
Fairouz Benahmed-Miniuk, Mat Kresz, Jitendra K Kanaujiya, Christopher D Southgate
Unlike with zinc finger nuclease and transcriptional activator-like effector nuclease DNA modification technologies that rely on lead proteins, developed through expensive and time-consuming processes, the clustered regularly interspaced short palindromic repeat (CRISPR)/Cas system has rapidly emerged as the most promising gene-editing technology to date for the modification of any selected DNA sequence. CRISPR is receiving tremendous fanfare due, in part, to its potential to provide a means to fundamentally alter medical genetics and especially cancer medicine...
May 2017: Pharmaceutical Patent Analyst
https://www.readbyqxmd.com/read/28343406/corrigendum
#20
(no author information available yet)
No abstract text is available yet for this article.
March 27, 2017: Pharmaceutical Patent Analyst
journal
journal
47821
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"